Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG

Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.

Description: A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）.

Trial Locations (1)

RECRUITING

Hunan Siweikang Therapeutic Co.Ltd, Changsha

All Listed Sponsors

lead

Anhui Provincial Hospital

OTHER_GOV

NCT06973356 - Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter